BNET Industries
Last Fiscal Year Sales:$35.9B
- Public
- DE
Dow Jones Description
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and improved earning power. We already successfully reorganized the Bayer Group and further streamlined our portfolio to create a new Bayer that is focused on its corporate strengths, its customers and the markets of the future. To help us achieve this goal, we then carried out a strategic realignment in order to concentrate in future on three high-potential, agile subgroups with largely independent operations: HealthCare, CropScience and MaterialScience, supported by three service companies. Our operating companies give us the access we need to the growth markets of the future. As an inventor company, we plan to continue setting trends in research-intensive areas. Innovations are the foundation for our competitiveness and our corporate growth, and thus for our success in the future. We believe our technical and commercial expertise entails a duty to contribute to sustainable development ? a principle we wholeheartedly endorse, mindful of its social, ethical and environmental elements. In awareness of our responsibilities as a corporate citizen, we define economy, ecology and social commitment as objectives of equal rank. We seek to retain society?s confidence through performance, flexibility and open communication as we work in pursuit of our overriding corporate goals: to steadily create corporate value and generate high value-added for the benefit of our stockholders, our employees and the community in every country in which we operate.
Director, Finance
Klaus KuhnNumber of Employees 122,100
Peer Companies
NAICS Code Plastics Material and Resin Manufacturing: 325211
Recent Events
-
Bayer and United Nations Environment Programme Launch 19th Annual International Children's...
-
Bayer Consumer Care Launches CitracalR Calcium Plus Heart Health
-
German drug, chemical company Bayer's Q3 net income falls 10 per cent
-
Bayer, US Onyx launch phase III trial of Nexavar in patients with non-responsive thyroid cancer
-
BRIEF-Credit Suisse raises targets on European pharma cos
-
Bayer accused of hiding Yaz contraceptive risk
-
Bayer downgraded to neutral from buy at UBS
-
Abbott Laboratories to acquire Solvay Pharmaceuticals
-
Bayer's contested kidney cancer drug shows benefit
-
Bayer names new CEO
-
Bayer Introduces CONTOUR USB - The First Blood Glucose Meter With Unique Plug & Play...
-
Bayer's next CEO has a year to prepare Today
-
Bayer AG tabs outsider as CEO's successor
-
Bayer Unveils Management Shuffle
News & Analysis
Filter by
bayer ag and fda - All News and Analysis
Bayer's Legal Woes: 125 Suits Over Yaz; FDA Allegedly Not Told of Trasylol Study
Bayer faces more than 125 lawsuits over its Yaz contraceptive and new cases are being filed around the country at a rate of up to up to six a day. Separately, a new suit filed over Trasylol alleges that Bayer failed to tell the FDA that a 67,000-patient study showed...
14 Drug Companies Cited for Misleading Google Ads
The FDA cited 14 drug companies for misleading advertising in sponsored ads among Google search results. Those cited: Biogen Idec, Sanofi Aventis, GlaxoSmithKline, Forest Laboratories, Cephalon, Bayer, Johnson & Johnson, Pfizer, Novartis , Genentech, Boehringer Ingelheim, Merck, Hoffman-LaRoche, and Eli Lilly. The citations, sent...
Why the Bayer-Yaz Settlement Will Not Change Drug Advertising Forever
Former Pfizer vp Dorothy Wetzel popped up in Ad Age today claiming that Bayer's corrective ad campaign for Yaz birth control "will cause drug companies to get way more conservative" with their advertising. "They're going to test and test and test their spots, and ultimately the advertising won't be as...
FDA Slams Bayer; Firm Has a History of Mismarketing OTC Medicines
FDA Slams Bayer; Firm Has a History of Mismarketing OTC MedicinesRE: FDA Slams Bayer; Firm Has a History of Mismarketing OTC MedicinesFrom the National Reye's Syndrome FoundationAnother blatant problem is the mismarketing of Low-Dose aspirin products as 'baby' or 'children's' aspirin.From the Bayer Website; Does Bayer make a "baby aspirin"?Yes....
Advertising Roundup: Google Ads Get Political, FDA Slaps Bayer for False Claims, and More
John Kerry urges Obama supporters to help by buying Google ads -- Senator John Kerry learned firsthand what happens when political opponents run successful smear campaigns, and he doesn't want Obama to suffer the same fate he did. Kerry is using his PAC to ask Obama supporters to buy Google...
FDA Slams Bayer; Firm Has a History of Mismarketing OTC Medicines
The FDA slammed Bayer with two warning letters today for allegedly unlawfully selling two unapproved aspirin products. It is not the first time Bayer's Consumer Health marketers have gone off the rails, raising questions about how professional -- or even scientific -- the company is when it comes to over-the-counter...
American Heart Association Advisory: Bayer Suspends Marketing of Aprotinin (Trasylol) at FDA Request
To: NATIONAL EDITORSTo: NATIONAL EDITORS
In Vitro Diagnostic (IVD) Directive Looks to Remove Technical Barriers to Trade and Assure Patients of Product Quality.
LONDON, December 6 /PRNewswire/ -- - Conformite Europeene CE Marking Will Allow Free Access to European Markets In a move aimed at harmonising diagnostics regulations, the European parliament amended the medical devices directive MDD of 1993 to bring in the...
Bayer HealthCare Receives FDA Approval for Kogenate® FS with BIO-SET®; Innovative Reconstitution System Will Offer Safety and Simplicity for People Living with Hemophilia A
BERKELEY, Calif. -- The Biological Products division of Bayer HealthCare LLC Bayer BP announced today that KogenateR FS (Antihemophilic Factor Recombinant, Formulated with Sucrose) with BIO-SETR has been approved by the United States Food and Drug Administration FDA. KogenateR FS with BIO-SETR becomes the first integrated reconstitution system for recombinant...
Bayer Receives FDA Approval for Room Temperature Storage of Kogenate® FS; Extended Storage Labeling Provides Greater Flexibility for Individuals Living with Hemophilia A
BERKELEY, Calif. -- The Biological Products Division of Bayer HealthCare, LLC., Bayer BP announced today that KogenateR FS (Antihemophilic Factor Recombinant, Formulated with Sucrose) received approval to be stored at room temperature (77 degrees F, 25 degrees C) for up to three months. The new storage guidelines for the treatment...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Klaus Kuhn | Director, Finance |
| Richard Pott | Director, Strategy and Human Resources |
| Wolfgang Plischke | Director, Innovation, Technology and Environment |
| Hartmut Klusik | Head, Product Supply |
| Gary S Balkema | Executive Committee Member |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Arthur J Higgins | Chairman, HealthCare |
| Werner Wenning | Executive Chairman |
| Klaus Kleinfeld | Board of Directors |
| Paul Achleitner | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Director, Finance | Current |
| University of South Carolina | MBA | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Director, Strategy and Human Resources | Current |
| University of Cologne | doctorate in physics | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Director, Innovation, Technology and Environment | Current |
| Bayer HealthCare AG | Manager | Current |
| Bayer HealthCare AG | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Head, Product Supply | Current |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Chairman, HealthCare | Current |
| Enzon Pharmaceuticals, Inc. | CEO | Former |
| Pharmaceutical Research and Manufacturers of America | member | Former |
| Bayer HealthCare, Animal Health Division | Chairman | Former |
| Enzon Pharmaceuticals, Inc. | Chairman | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Executive Chairman | Current |
| Henkel AG & Co. KGaA | Supervisory Board | Current |
Klaus Kleinfeld is president and chief executive officer of Alcoa. He joined the company in 2007 as president and chief operating officer and seven months later assumed CEO responsibilities. He has served on Alcoa's board of directors since 2003. Alcoa is a world leader in the production and management of a very sustainable product: aluminum. Nearly 75% of the aluminum ever produced since 1888 is still in use today. The company has been a technology leader since its beginning, providing more than 90% of the aluminum alloys used in aircraft and space flight; helping making automobiles lighter, without compromising safety or performance; manufacturing sheet that created the ultimate recyclable container, the aluminum beverage can; and providing building and construction industry materials that help further the green building movement. In addition, to serving customers in these markets, Alcoa also markets wheels, fastening systems, precision and investment castings, and building systems. The company has 97,000 employees in 34 countries. Before coming to Alcoa, Mr. Kleinfeld had a 20-year career with Siemens, the global electronics and industrial conglomerate, based in the U.S. and Germany, where he served as chief executive officer of Siemens AG starting in 2005. During his tenure, Mr. Kleinfeld presided over a dramatic transformation of the company, reshaping the company's portfolio around three high growth areas, resulting in increase of revenues and market capitalization nearly doubled. Prior to his service on the Managing Board of Siemens AG, Mr. Kleinfeld was President and Chief Executive Officer of Siemens Corporation, its U.S. arm and the company's largest region. In addition to serving on Alcoa's board, he is a member of the board of Bayer AG. On the personal front, Mr. Kleinfeld was born in Bremen, Germany and educated at the University of Goettingen and University of Wuerzburg, both in Germany. He holds a Ph.D in strategic management and master's degree in business administration. In his leisure time, he enjoys skiing, tennis, the arts and is a marathon runner. Mr. Kleinfeld resides in New York with his wife and children.
| Organization | Position | Status |
|---|---|---|
| Alcoa, Inc. | President & Chief Executive Officer | Current |
| Bayer AG | Board of Directors | Current |
| Alcoa, Inc. | Board of Directors | Current |
| Siemens AG | President & CEO | Former |
| Siemens Corporation | Chief Executive Officer | Former |
| Alcoa, Inc. | Chief Operating Officer | Former |
| Siemens Corporation | Chief Operating Officer | Former |
| Siemens AG | Chief Operations Officer, U.S. | Former |
| Siemens AG | Executive Vice President | Former |
| Siemens AG | Audit Committee Principal | Former |
| Citigroup Inc. | Board of Directors | Former |
| Siemens AG | Board of Directors | Former |
| Siemens Corporation | member | Former |
| Organization | Position | Status |
|---|---|---|
| Allianz SE | Executive Director, Finance | Current |
| Bayer AG | Board of Directors | Current |
| Goldman, Sachs & Co. | Vice President, Mergers & Acquisitions | Former |
| Bain & Company | Manager, Strategy Consulting | Former |
| Organization | Position | Status |
|---|---|---|
| Bayer AG | Executive Committee Member | Current |
| Bayer HealthCare, Animal Health Division | President, Worldwide Bayer Consumer Care Division | Former |
| Fairleigh Dickinson University | master of business administration degree | Former |
Executive News
-
Report from Europe: U.S. Close vs. China Rebound
-
Alcoa Named Component of Dow Jones Sustainability Index for Eighth Consecutive Year
-
Alcoa says global aluminium demand to fall 5.5 pct -Bloomberg
-
Siemens To Settle Bribery Charges with Three Former Execs
-
Siemens poised to settle with ex-managers
-
UPDATE 1-Siemens poised to settle with ex-managers
-
UPDATE 1-Siemens poised to settle with ex-managers
-
Bayer AG (BAY.F) May Be Ready for Deals After Lost Intervet Bid
-
Inventories May Temper Aluminum Rally
Industry Transcripts by Seeking Alpha
-
Deere & Company F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Nov 25, 2009about DE
-
Brown Shoe Co. Inc. Q3 2009 Earnings Call Transcript
on Nov 24, 2009about BWS
-
Daktronics Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Nov 24, 2009about DAKT
-
Haynes International Inc. F4Q09 (Qtr End 09/30/09) Earnings Call Transcript
on Nov 24, 2009about HAYN
-
Valspar Corp. F4Q09 (Qtr End 30/10/09) Earnings Call Transcript
on Nov 23, 2009about VAL

